Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
A PHASE 2A, EXPLORATORY, TWO-PART, OPEN-LABLE TRIAL TO EVALUATE DOSE AND SAFETY OF NANOECHO PARTICLE-1 (FERUMOXTRAN) USING NANOECHO IMAGIN… Recruiting

2024-515335-29-00 Rectal cancer 4 2024-10-16
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Metastatic Colorectal Cancer 5 2024-10-14
Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation Recruiting

2022-501892-14-00 Prostate cancer 5 2024-10-14
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi… Recruiting

2024-514620-17-00 Patients with early-stage rectal cancer (defined as ear 4 2024-10-14
68Ga-FAPI-46 PET/CT for predicting histological response in triple-negative breast cancer Recruiting

2023-507860-37-00 Breast cancer 9 2024-10-14
Diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer Recruiting

2024-510651-35-00 Colon cancer 4 2024-10-14
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Triple-negative early breast cancer with low risk for r 4 2024-10-10
IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting

2023-506686-66-01 HLA-A2 negative metastatic uveal melanoma 10 2024-10-09
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Pancreatic Cancer Recruiting

2023-510208-39-00 Pancreatic cancer 4 2024-10-09
Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma Recruiting

2024-516547-11-00 skincancer 4 2024-10-08
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY AC… Recruiting

2024-515737-14-00 Acute leukemia and myelodysplastic syndromes 3 2024-10-07
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
BORTEM 17 Recruiting

2024-515142-16-00 Grade IV recurrent glioma which includes both glioblast 7 2024-10-03
The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Quality of Life Recruiting

2024-513437-21-00 Cancer 6 2024-10-02
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A clinical imaging Study of the changes in [18F]F-AraG uptake following Radiotherapy in Non-small cell lung cancer. Recruiting

2024-517960-45-00 Melanoma 9 2024-10-02
(NFPET) 89Zr-Bevacizumab PET/CT imaging in NF2 patients Recruiting

2024-512860-75-00 NF2-related schwannomatosis 4 2024-10-01
A lower dose olaparib, combined with a drug which inhibits olaparib degradation, to increase tolerability and decrease the price of the trea… Recruiting

2024-516414-38-00 Cancer 11 2024-10-01
An extension study for patients previously enrolled in studies with pelabresib Recruiting

2023-508950-24-00 Myelofibrosis 5 2024-10-01
OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting

2023-509073-23-00 Stage III/IV non-small-cell lung cancer (NSCLC) harbori 4 2024-10-01
Maintenance of durvalumab and olaparib after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive ext… Recruiting

2024-512373-27-00 Advanced/inoperable or metastatic small-cell lung cance 4 2024-09-30
A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting

2023-510136-36-00 Advanced Non-Hodgkin’s Lymphoma 1 2024-09-27